ZyVersa Therapeutics, Inc. (ZVSA): R&D Expense
$1.11M
Year ended 2025-12-31
$911.9K
Trailing 12 months to 2026-03-31
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.11M | -37.4% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $1.78M | -44.5% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $3.21M | n/a | 2025-03-27, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| ZyVersa Therapeutics, Inc. (ZVSA) | 2025-12-31 | $1.11M | -37.4% |
| Regen BioPharma Inc (RGBP) | 2025-09-30 | $11.7K | -92.4% |
| ProtoKinetix, Inc. (PKTX) | 2025-12-31 | $106.6K | +7.0% |
| Bioxytran, Inc (BIXT) | 2025-12-31 | $454.0K | +304.1% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
| Ocean Biomedical, Inc. (OCEA) | 2024-12-31 | $26.0K | -96.3% |
| NeuroSense Therapeutics Ltd. (NRSN) | 2025-12-31 | $6.23M | +9.3% |
| Aspire Biopharma Holdings, Inc. (ASBP) | 2025-12-31 | $923.9K | +540.0% |
| Semnur Pharmaceuticals, Inc. (SMNR) | 2025-12-31 | $2.55M | +49.0% |
Compare ZVSA, RGBP, PKTX, BIXT side by side · Screen every company in Pharmaceutical Preparations ↗